UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The Transition-State Structure for Human MAT2A from Isotope Effects

Journal of the American Chemical Society, 2017-10, Vol.139 (39), p.13754-13760

2017

Volltextzugriff (PDF)

Transition state analogue of MTAP extends lifespan of APCMin/+ mice

Scientific reports, 2021-04, Vol.11 (1), p.1-11, Article 8844

2021

Volltextzugriff (PDF)

Kinetic Isotope Effects and Transition State Structure for Hypoxanthine-Guanine-Xanthine Phosphoribosyltransferase from Plasmodium falciparum

Biochemistry (Easton), 2017-12, Vol.56 (48), p.6368-6376

2017

Volltextzugriff (PDF)

Selective Inhibitors of Helicobacter pylori Methylthioadenosine Nucleosidase and Human Methylthioadenosine Phosphorylase

Journal of medicinal chemistry, 2019-04, Vol.62 (7), p.3286-3296

2019

Volltextzugriff (PDF)

Continuous Fluorescence Assays for Reactions Involving Adenine

Analytical chemistry (Washington), 2016-12, Vol.88 (23), p.11860-11867

2016

Volltextzugriff (PDF)

Heat Capacity Changes for Transition-State Analogue Binding and Catalysis with Human 5′-Methylthioadenosine Phosphorylase

ACS chemical biology, 2017-02, Vol.12 (2), p.464-473

2017

Volltextzugriff (PDF)

Microwave spectra, structure, and dynamics of the weakly bound complex, N2 CO2

The Journal of chemical physics, 2010-12, Vol.133 (24), p.244303-244303

2010

Volltextzugriff (PDF)

P962: COMMERCIAL TECLISTAMAB IN ANTI‐BCMA THERAPY EXPOSED RELAPSED REFRACTORY MULTIPLE MYELOMA PATIENTS: THE MSKCC EXPERIENCE

HemaSphere, 2023-08, Vol.7 (S3), p.e81198bb-n/a

2023

Volltextzugriff (PDF)

The Effects of Low‐Level Laser Light Exposure on Sperm Motion Characteristics and DNA Damage

Journal of andrology, 2012-05, Vol.33 (3), p.469-473

2012

Volltextzugriff (PDF)

Abstract 18: Doubled lifespan in APCMin/+ mice by targeting MTAP

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.18-18

2019

Volltextzugriff (PDF)

P-247 Increased WEE1 Expression Is Predictive of Short Progression-Free Survival, Independent of Standard Prognostic Factors in Multiple Myeloma

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S180-S180

2024

Volltextzugriff (PDF)

Patterns of Cytokine Release Syndrome with Teclistamab in Relapsed/Refractory Multiple Myeloma with or without Prior T-Cell Redirection Therapy

Blood, 2023-11, Vol.142 (Supplement 1), p.1961-1961

2023

Volltextzugriff (PDF)

Evaluating Tumor-Intrinsic and Patient-Specific Mechanisms of Resistance to Teclistamab in Anti-BCMA Exposed and Naïve Multiple Myeloma

Blood, 2023-11, Vol.142 (Supplement 1), p.333-333

2023

Volltextzugriff (PDF)

Clinical Outcomes Associated with Del(17p) in Newly Diagnosed Multiple Myeloma Treated with Triplet and Daratumumab-Based Quadruplet Induction Regimens

Blood, 2023-11, Vol.142 (Supplement 1), p.2024-2024

2023

Volltextzugriff (PDF)

Evaluating the efficacy of commercial teclistamab in relapsed refractory multiple myeloma patients with prior exposure to anti-BCMA therapies

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.8049-8049

2023

Volltextzugriff (PDF)

OA-15 Maintenance Therapy Cessation for Multiple Myeloma Patients with Three-Year Sustained MRD Negative Remissions

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S10-S11

2024

Volltextzugriff (PDF)

P-486 Clinical significance of baseline body mass index and its trajectory during triplet induction therapy in newly diagnosed multiple myeloma

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S307-S308

2023

Volltextzugriff (PDF)

P-038 Phase I Trial of MCARH109, a First-in-Class G Protein Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted CAR T-cell Therapy for Relapsed or Refractory Multiple Myeloma: Updated Analysis

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S62-S63

2024

Volltextzugriff (PDF)

P-012 Real-World Safety and Early Efficacy of Talquetamab in Patients with Heavily-Pretreated Relapsed/Refractory Multiple Myeloma

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S46-S47

2024

Volltextzugriff (PDF)

P-011 Impact of Daratumumab Refractoriness on Clinical Outcomes Following CAR T-cell Therapy for Relapsed/Refractory Multiple Myeloma

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S46-S46

2024

Volltextzugriff (PDF)

P-232 Comprehensive Genomic Sequencing Predicts Sub-Optimal Response to Bispecific Antibodies (BsAb) and Chimeric Antigen Receptor T Cells (CAR-T) in Multiple Myeloma (MM)

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S171-S172

2024

Volltextzugriff (PDF)

P-039 CMV Reactivation During Treatment with Bispecific Antibodies for Relapsed/Refractory Multiple Myeloma

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S63-S64

2024

Volltextzugriff (PDF)

P-095 Impact of Granulocyte Colony-Stimulating Factor Exposure on Cytokine Release Syndrome During Bispecific Antibody Initiation in Relapsed/Refractory Multiple Myeloma

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S97-S97

2024

Volltextzugriff (PDF)

P-268 Defining the Rates of Cytokine Release Syndrome Associated with Talquetamab Step-up Doses

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S191-S191

2024

Volltextzugriff (PDF)

1 – 25 von 50

Suche als RSS-Feed

Aktive Filter

ThemaHematology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(45)
Mit Volltextzugriff
(41)

Publikationsform

Sprache

Englisch
(49)

Erscheinungsjahr

n.n

Thema

Science & Technology
(17)
Life Sciences & Biomedicine
(13)
Humans
(9)
Animals
(5)
Biochemistry & Molecular Biology
(5)
Kinetics
(4)
Female
(3)
Male
(3)
Purine-Nucleoside Phosphorylase - Metabolism
(3)
Rats
(3)
Actors
(2)
Adenine - Analogs & Derivatives
(2)
Binding Sites
(2)
Biochemistry
(2)
Biological And Medical Sciences
(2)
Catalysis
(2)
Ccaat-Enhancer-Binding Proteins
(2)
Cell Biology
(2)
Chemistry
(2)
Dexamethasone - Pharmacology
(2)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(10)

Menü

Weitere Dienste

Einstellungen

The Transition-State Structure for Human MAT2A from Isotope Effects

Transition state analogue of MTAP extends lifespan of APCMin/+ mice

Kinetic Isotope Effects and Transition State Structure for Hypoxanthine-Guanine-Xanthine Phosphoribosyltransferase from Plasmodium falciparum

Selective Inhibitors of Helicobacter pylori Methylthioadenosine Nucleosidase and Human Methylthioadenosine Phosphorylase

Continuous Fluorescence Assays for Reactions Involving Adenine

Heat Capacity Changes for Transition-State Analogue Binding and Catalysis with Human 5′-Methylthioadenosine Phosphorylase

Microwave spectra, structure, and dynamics of the weakly bound complex, N2 CO2

P962: COMMERCIAL TECLISTAMAB IN ANTI‐BCMA THERAPY EXPOSED RELAPSED REFRACTORY MULTIPLE MYELOMA PATIENTS: THE MSKCC EXPERIENCE

The Effects of Low‐Level Laser Light Exposure on Sperm Motion Characteristics and DNA Damage

Abstract 18: Doubled lifespan in APCMin/+ mice by targeting MTAP

P-247 Increased WEE1 Expression Is Predictive of Short Progression-Free Survival, Independent of Standard Prognostic Factors in Multiple Myeloma

Patterns of Cytokine Release Syndrome with Teclistamab in Relapsed/Refractory Multiple Myeloma with or without Prior T-Cell Redirection Therapy

Identifying Causes of Unscheduled Healthcare Interactions and Changes to Patient Disposition in Individuals Receiving Outpatient Commercial Bispecific Antibody Therapy in Relapsed/Refractory Multiple Myeloma (RRMM)

Evaluating Tumor-Intrinsic and Patient-Specific Mechanisms of Resistance to Teclistamab in Anti-BCMA Exposed and Naïve Multiple Myeloma

Clinical Outcomes Associated with Del(17p) in Newly Diagnosed Multiple Myeloma Treated with Triplet and Daratumumab-Based Quadruplet Induction Regimens

Evaluating the efficacy of commercial teclistamab in relapsed refractory multiple myeloma patients with prior exposure to anti-BCMA therapies

OA-15 Maintenance Therapy Cessation for Multiple Myeloma Patients with Three-Year Sustained MRD Negative Remissions

P-486 Clinical significance of baseline body mass index and its trajectory during triplet induction therapy in newly diagnosed multiple myeloma

P-038 Phase I Trial of MCARH109, a First-in-Class G Protein Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted CAR T-cell Therapy for Relapsed or Refractory Multiple Myeloma: Updated Analysis

P-012 Real-World Safety and Early Efficacy of Talquetamab in Patients with Heavily-Pretreated Relapsed/Refractory Multiple Myeloma

P-011 Impact of Daratumumab Refractoriness on Clinical Outcomes Following CAR T-cell Therapy for Relapsed/Refractory Multiple Myeloma

P-232 Comprehensive Genomic Sequencing Predicts Sub-Optimal Response to Bispecific Antibodies (BsAb) and Chimeric Antigen Receptor T Cells (CAR-T) in Multiple Myeloma (MM)

P-039 CMV Reactivation During Treatment with Bispecific Antibodies for Relapsed/Refractory Multiple Myeloma

P-095 Impact of Granulocyte Colony-Stimulating Factor Exposure on Cytokine Release Syndrome During Bispecific Antibody Initiation in Relapsed/Refractory Multiple Myeloma

P-268 Defining the Rates of Cytokine Release Syndrome Associated with Talquetamab Step-up Doses

Aktive Filter

Suchergebnisse filtern